Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
Pluristem initiated with a Buy at Alliance Global Partners » 08:06
05/04/21
05/04
08:06
05/04/21
08:06
PSTI

Pluristem

/

+

Alliance Global Partners…

Alliance Global Partners analyst James Molloy initiated coverage of Pluristem with a Buy rating and $12.50 price target. He believes that PLX-PAD, the company's allogeneic placenta-based cell therapy, for the treatment of multiple ischemic, inflammatory and hematologic conditions could be a significant improvement for patients recovering from hip surgery. Molloy also sees potential for PLX-PAD use in patients with Acute Respiratory Distress Syndrome associated with COVID-19, he said.

ShowHide Related Items >><<
PSTI Pluristem
/

+

PSTI Pluristem
/

+

12/10/20 H.C. Wainwright
Pluristem price target lowered to $9 from $15.50 at H.C. Wainwright
12/10/20 Jefferies
Pluristem downgraded to Hold from Buy at Jefferies
07/24/20 Jefferies
Pluristem price target raised to $16 from $12 at Jefferies
06/22/20 Dawson James
Channel checks dispute NY Times' COVID contention, says Dawson James
PSTI Pluristem
/

+

PSTI Pluristem
/

+

Conference/Events
Pluristem to host conference call » 09:30
05/03/21
05/03
09:30
05/03/21
09:30
PSTI

Pluristem

$4.25 /

-0.05 (-1.16%)

Conference call to…

Conference call to discuss the Hematology Program Phase 1 Topline results will be held on May 3 at 10 am. Webcast Link

ShowHide Related Items >><<
PSTI Pluristem
$4.25 /

-0.05 (-1.16%)

PSTI Pluristem
$4.25 /

-0.05 (-1.16%)

12/10/20 H.C. Wainwright
Pluristem price target lowered to $9 from $15.50 at H.C. Wainwright
12/10/20 Jefferies
Pluristem downgraded to Hold from Buy at Jefferies
07/24/20 Jefferies
Pluristem price target raised to $16 from $12 at Jefferies
06/22/20 Dawson James
Channel checks dispute NY Times' COVID contention, says Dawson James
PSTI Pluristem
$4.25 /

-0.05 (-1.16%)

PSTI Pluristem
$4.25 /

-0.05 (-1.16%)

On The Fly
Fly Intel: Pre-market Movers » 09:00
04/29/21
04/29
09:00
04/29/21
09:00
CAT

Caterpillar

$232.60 /

+2.21 (+0.96%)

, KHC

Kraft Heinz

$40.11 /

-0.03 (-0.07%)

, HSY

Hershey

$158.93 /

+0.155 (+0.10%)

, RCL

Royal Caribbean

$87.45 /

-0.26 (-0.30%)

, TAP

Molson Coors

$51.86 /

-0.2 (-0.38%)

, BLMN

Bloomin' Brands

$28.80 /

+0.105 (+0.37%)

, AAPL

Apple

$133.80 /

-0.58 (-0.43%)

, FB

Facebook

$307.26 /

+3.755 (+1.24%)

, MRK

Merck

$77.12 /

-0.23 (-0.30%)

, TMO

Thermo Fisher

$486.20 /

-4.61 (-0.94%)

, BMY

Bristol-Myers

$66.04 /

+0.08 (+0.12%)

, IP

International Paper

$57.88 /

+0.71 (+1.24%)

, TDOC

Teladoc

$186.31 /

-3.49 (-1.84%)

, ADVM

Adverum Biotechnologies

$10.16 /

+0.29 (+2.94%)

, PLBY

PLBY Group

$49.70 /

-2.45 (-4.70%)

, PSTI

Pluristem

$4.55 /

+0.08 (+1.79%)

, MA

MasterCard

$395.79 /

+6.78 (+1.74%)

, CMCSA

Comcast

$54.14 /

-0.16 (-0.29%)

, CMCSK

Comcast

$58.00 /

+ (+0.00%)

Check out this morning's…

ShowHide Related Items >><<
TMO Thermo Fisher
$486.20 /

-4.61 (-0.94%)

TDOC Teladoc
$186.31 /

-3.49 (-1.84%)

TAP Molson Coors
$51.86 /

-0.2 (-0.38%)

RCL Royal Caribbean
$87.45 /

-0.26 (-0.30%)

PSTI Pluristem
$4.55 /

+0.08 (+1.79%)

PLBY PLBY Group
$49.70 /

-2.45 (-4.70%)

MRK Merck
$77.12 /

-0.23 (-0.30%)

MA MasterCard
$395.79 /

+6.78 (+1.74%)

KHC Kraft Heinz
$40.11 /

-0.03 (-0.07%)

IP International Paper
$57.88 /

+0.71 (+1.24%)

HSY Hershey
$158.93 /

+0.155 (+0.10%)

FB Facebook
$307.26 /

+3.755 (+1.24%)

CMCSK Comcast
$58.00 /

+ (+0.00%)

CMCSA Comcast
$54.14 /

-0.16 (-0.29%)

CAT Caterpillar
$232.60 /

+2.21 (+0.96%)

BMY Bristol-Myers
$66.04 /

+0.08 (+0.12%)

BLMN Bloomin' Brands
$28.80 /

+0.105 (+0.37%)

ADVM Adverum Biotechnologies
$10.16 /

+0.29 (+2.94%)

AAPL Apple
$133.80 /

-0.58 (-0.43%)

CAT Caterpillar
$232.60 /

+2.21 (+0.96%)

04/13/21 Deutsche Bank
Caterpillar price target raised to $259 from $232 at Deutsche Bank
04/12/21 Wolfe Research
Caterpillar initiated with an Outperform at Wolfe Research
04/01/21 Evercore ISI
Caterpillar said to be planning mid-year price increase, says Evercore ISI
03/16/21 Citi
Caterpillar price target raised to $245 from $205 at Citi
KHC Kraft Heinz
$40.11 /

-0.03 (-0.07%)

04/23/21
Fly Intel: Top five analyst downgrades
04/23/21 Piper Sandler
Kraft Heinz downgraded on valuation, cost headwinds at Piper Sandler
04/22/21 Piper Sandler
Kraft Heinz downgraded to Neutral from Overweight at Piper Sandler
02/19/21 JPMorgan
Kraft Heinz downgraded to Neutral on valuation at JPMorgan
HSY Hershey
$158.93 /

+0.155 (+0.10%)

04/15/21
Fly Intel: Top five analyst upgrades
04/15/21 Goldman Sachs
Hershey upgraded to Buy from Neutral at Goldman Sachs
03/17/21
Fly Intel: Top five analyst upgrades
03/17/21 Piper Sandler
Hershey upgraded to Overweight on cost visibility at Piper Sandler
RCL Royal Caribbean
$87.45 /

-0.26 (-0.30%)

04/23/21 Morgan Stanley
Royal Caribbean price target raised to $61 from $50 at Morgan Stanley
04/21/21 Berenberg
Royal Caribbean price target raised to $70 from $55 at Berenberg
04/21/21 Goldman Sachs
Royal Caribbean price target raised to $95 from $76 at Goldman Sachs
03/24/21 Stifel
Cruiseline stock selloff 'unwarranted,' says Stifel
TAP Molson Coors
$51.86 /

-0.2 (-0.38%)

04/12/21 Wolfe Research
Molson Coors initiated with a Peer Perform at Wolfe Research
03/31/21 Citi
Molson Coors price target raised to $61 from $52 at Citi
03/29/21 JPMorgan
Molson Coors price target raised to $46 from $43 at JPMorgan
03/19/21
Fly Intel: Top five analyst downgrades
BLMN Bloomin' Brands
$28.80 /

+0.105 (+0.37%)

04/16/21 Deutsche Bank
Bloomin' Brands price target raised to $31 from $28 at Deutsche Bank
04/15/21 Wells Fargo
Bloomin' Brands price target raised to $33 from $26 at Wells Fargo
04/12/21 JPMorgan
Bloomin' Brands price target raised to $32 from $30 at JPMorgan
04/01/21 MKM Partners
Bloomin' Brands price target raised to $32 from $27 at MKM Partners
AAPL Apple
$133.80 /

-0.58 (-0.43%)

04/29/21 Canaccord
Apple price target raised to $165 from $155 at Canaccord
04/29/21 Evercore ISI
Evercore says Apple had 'trifecta' of demand, margins and monetization in Q2
04/29/21 Credit Suisse
Apple price target raised to $150 from $140 at Credit Suisse
04/29/21 Wells Fargo
Wells Fargo sees positive reaction in shares of Apple as 'justified'
FB Facebook
$307.26 /

+3.755 (+1.24%)

04/29/21 Canaccord
Facebook price target raised to $380 from $350 at Canaccord
04/29/21 Credit Suisse
Facebook price target raised to $400 from $371 at Credit Suisse
04/29/21 Jefferies
Facebook price target raised to $385 from $360 at Jefferies
04/29/21 Monness Crespi
Facebook price target raised to $460 from $375 at Monness Crespi
MRK Merck
$77.12 /

-0.23 (-0.30%)

04/20/21 Citi
GlaxoSmithKline collaboration with Merck would be 'win-win,' says Citi
04/16/21 William Blair
Atea selloff on Merck update unwarranted, says William Blair
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
04/08/21 Alliance Global Partners
Alliance Global Partners sees Fast Track for Immutep efti as meaningful positive
TMO Thermo Fisher
$486.20 /

-4.61 (-0.94%)

04/28/21 JPMorgan
PPD downgraded to Neutral from Overweight at JPMorgan
04/19/21 Citi
PPD downgraded to Neutral from Buy at Citi
04/19/21 Mizuho
PPD downgraded to Neutral from Buy at Mizuho
04/19/21 Credit Suisse
PPD downgraded to Neutral from Outperform at Credit Suisse
BMY Bristol-Myers
$66.04 /

+0.08 (+0.12%)

04/21/21 Citi
Citi sees 'material upside' for AbbVie, Bristol-Myers after Pfizer data
04/21/21 Citi
Citi opens '90-day catalyst watch' on Bristol-Myers, reiterates Buy
04/13/21 Truist
Bristol-Myers upgraded to Buy at Truist on improving pipeline asset visibility
04/13/21 Truist
Bristol-Myers upgraded to Buy from Hold at Truist
IP International Paper
$57.88 /

+0.71 (+1.24%)

04/19/21 Deutsche Bank
International Paper price target raised to $58 from $49 at Deutsche Bank
03/22/21 BMO Capital
Friday night 'big disappointment' for paperboard companies, says BMO Capital
02/05/21
Fly Intel: Top five analyst upgrades
02/05/21 Seaport Global
International Paper upgraded to Buy from Neutral at Seaport Global
TDOC Teladoc
$186.31 /

-3.49 (-1.84%)

04/29/21 Canaccord
Teladoc price target lowered to $295 from $330 at Canaccord
04/29/21 BTIG
Teladoc price target lowered to $300 from $330 at BTIG
04/29/21 Oppenheimer
Teladoc price target lowered to $250 from $270 at Oppenheimer
04/29/21 Piper Sandler
Teladoc has 'multiple potential drivers' to estimate upside, says Piper Sandler
ADVM Adverum Biotechnologies
$10.16 /

+0.29 (+2.94%)

04/29/21 Truist
Adverum Biotechnologies downgraded to Hold from Buy at Truist
04/29/21 Truist
Adverum Biotechnologies downgraded to Hold from Buy at Truist
04/29/21 RBC Capital
Adverum Biotech cut to Sector Perform at RBC after SUSAR in ADVM-022 trial
04/29/21 RBC Capital
Adverum Biotechnologies downgraded to Sector Perform from Outperform at RBC Capital
PLBY PLBY Group
$49.70 /

-2.45 (-4.70%)

04/07/21 Roth Capital
PLBY Group price target raised to $35 from $26 at Roth Capital
04/06/21 Canaccord
Canaccord sees Nifty Gateway partnership as initial step in PLBY's NFT strategy
03/31/21 Canaccord
PLBY Group initiated with a Buy at Canaccord
03/24/21 Craig-Hallum
PLBY Group price target raised to $35 from $25 at Craig-Hallum
PSTI Pluristem
$4.55 /

+0.08 (+1.79%)

12/10/20 H.C. Wainwright
Pluristem price target lowered to $9 from $15.50 at H.C. Wainwright
12/10/20 Jefferies
Pluristem downgraded to Hold from Buy at Jefferies
07/24/20 Jefferies
Pluristem price target raised to $16 from $12 at Jefferies
06/22/20 Dawson James
Channel checks dispute NY Times' COVID contention, says Dawson James
MA MasterCard
$395.79 /

+6.78 (+1.74%)

04/28/21 Credit Suisse
Visa price target raised to $280 from $270 at Credit Suisse
04/20/21 Morgan Stanley
MasterCard price target raised to $418 from $412 at Morgan Stanley
04/20/21 Barclays
MasterCard price target raised to $402 from $380 at Barclays
04/13/21 Morgan Stanley
Synchrony loss of Gap card deal 'likely a positive,' says Morgan Stanley
CMCSA Comcast
$54.14 /

-0.16 (-0.29%)

04/16/21
Fly Intel: Top five analyst upgrades
04/16/21 Raymond James
Comcast upgraded to Outperform from Market Perform at Raymond James
04/16/21 Raymond James
Comcast upgraded to Outperform from Market Perform at Raymond James
04/12/21 Pivotal Research
Comcast price target raised to $65 from $63 at Pivotal Research
CMCSK Comcast
$58.00 /

+ (+0.00%)

02/23/21 Credit Suisse
SeaWorld price target raised to $52 from $34 at Credit Suisse
10/07/20 Benchmark
Benchmark would be 'aggressive buyer' of Comcast amid broader market weakness
09/22/20 Benchmark
Comcast price target raised to $60 from $54 at Benchmark
09/16/20 Pivotal Research
Comcast price target raised to $60 from $52 at Pivotal Research
TMO Thermo Fisher
$486.20 /

-4.61 (-0.94%)

TDOC Teladoc
$186.31 /

-3.49 (-1.84%)

TAP Molson Coors
$51.86 /

-0.2 (-0.38%)

RCL Royal Caribbean
$87.45 /

-0.26 (-0.30%)

PLBY PLBY Group
$49.70 /

-2.45 (-4.70%)

MRK Merck
$77.12 /

-0.23 (-0.30%)

MA MasterCard
$395.79 /

+6.78 (+1.74%)

KHC Kraft Heinz
$40.11 /

-0.03 (-0.07%)

IP International Paper
$57.88 /

+0.71 (+1.24%)

HSY Hershey
$158.93 /

+0.155 (+0.10%)

FB Facebook
$307.26 /

+3.755 (+1.24%)

CMCSA Comcast
$54.14 /

-0.16 (-0.29%)

CAT Caterpillar
$232.60 /

+2.21 (+0.96%)

BMY Bristol-Myers
$66.04 /

+0.08 (+0.12%)

BLMN Bloomin' Brands
$28.80 /

+0.105 (+0.37%)

ADVM Adverum Biotechnologies
$10.16 /

+0.29 (+2.94%)

AAPL Apple
$133.80 /

-0.58 (-0.43%)

  • 01
    Mar
  • 10
    Nov
  • 14
    Oct
  • 13
    Aug
TMO Thermo Fisher
$486.20 /

-4.61 (-0.94%)

RCL Royal Caribbean
$87.45 /

-0.26 (-0.30%)

PLBY PLBY Group
$49.70 /

-2.45 (-4.70%)

MRK Merck
$77.12 /

-0.23 (-0.30%)

MA MasterCard
$395.79 /

+6.78 (+1.74%)

KHC Kraft Heinz
$40.11 /

-0.03 (-0.07%)

HSY Hershey
$158.93 /

+0.155 (+0.10%)

FB Facebook
$307.26 /

+3.755 (+1.24%)

CMCSK Comcast
$58.00 /

+ (+0.00%)

CMCSA Comcast
$54.14 /

-0.16 (-0.29%)

CAT Caterpillar
$232.60 /

+2.21 (+0.96%)

BMY Bristol-Myers
$66.04 /

+0.08 (+0.12%)

BLMN Bloomin' Brands
$28.80 /

+0.105 (+0.37%)

AAPL Apple
$133.80 /

-0.58 (-0.43%)

TMO Thermo Fisher
$486.20 /

-4.61 (-0.94%)

TDOC Teladoc
$186.31 /

-3.49 (-1.84%)

TAP Molson Coors
$51.86 /

-0.2 (-0.38%)

RCL Royal Caribbean
$87.45 /

-0.26 (-0.30%)

PSTI Pluristem
$4.55 /

+0.08 (+1.79%)

MRK Merck
$77.12 /

-0.23 (-0.30%)

MA MasterCard
$395.79 /

+6.78 (+1.74%)

KHC Kraft Heinz
$40.11 /

-0.03 (-0.07%)

IP International Paper
$57.88 /

+0.71 (+1.24%)

HSY Hershey
$158.93 /

+0.155 (+0.10%)

FB Facebook
$307.26 /

+3.755 (+1.24%)

CMCSK Comcast
$58.00 /

+ (+0.00%)

CMCSA Comcast
$54.14 /

-0.16 (-0.29%)

CAT Caterpillar
$232.60 /

+2.21 (+0.96%)

BMY Bristol-Myers
$66.04 /

+0.08 (+0.12%)

AAPL Apple
$133.80 /

-0.58 (-0.43%)

TDOC Teladoc
$186.31 /

-3.49 (-1.84%)

TAP Molson Coors
$51.86 /

-0.2 (-0.38%)

RCL Royal Caribbean
$87.45 /

-0.26 (-0.30%)

PSTI Pluristem
$4.55 /

+0.08 (+1.79%)

PLBY PLBY Group
$49.70 /

-2.45 (-4.70%)

MRK Merck
$77.12 /

-0.23 (-0.30%)

MA MasterCard
$395.79 /

+6.78 (+1.74%)

KHC Kraft Heinz
$40.11 /

-0.03 (-0.07%)

IP International Paper
$57.88 /

+0.71 (+1.24%)

FB Facebook
$307.26 /

+3.755 (+1.24%)

CMCSA Comcast
$54.14 /

-0.16 (-0.29%)

CAT Caterpillar
$232.60 /

+2.21 (+0.96%)

BMY Bristol-Myers
$66.04 /

+0.08 (+0.12%)

BLMN Bloomin' Brands
$28.80 /

+0.105 (+0.37%)

AAPL Apple
$133.80 /

-0.58 (-0.43%)

Hot Stocks
Pluristem reports Phase I results studying PLX-R18 in humans » 07:31
04/29/21
04/29
07:31
04/29/21
07:31
PSTI

Pluristem

$4.55 /

+0.08 (+1.79%)

Pluristem Therapeutics…

Pluristem Therapeutics reported "positive" results in its first study to evaluate the safety and exploratory efficacy of PLX-R18 in humans. The company's Phase I, open-label, dose-escalation study is evaluating the safety and exploratory efficacy of intramuscular injections of PLX-R18 in subjects with incomplete hematopoietic recovery following Hematopoietic Cell Transplantation. The study enrolled 21 patients in the U.S. and Israel, who were at least three months after the HCT procedure, and had low blood counts in at least one blood cell lineage. They were assigned to one of three treatment arms: 1 million cells/kg, 2 million cells/kg or 4 million cells/kg. Each patient received two treatments of the assigned dose. The results demonstrate that PLX-R18 has the potential to stimulate the implanted hematopoietic cells to realize their therapeutic potential and generate improved blood counts over the long term in all three blood cell lineages at once - a meaningful advantage over other existing and proposed treatments. Available data1 at six-month follow-up demonstrates: PLX-R18 was well-tolerated with a favorable safety profile; statistically significant improvement from baseline counts was observed in all cohorts for hemoglobin and platelet counts; the patients in the high dose arm exhibited statistically significant improvements in all three blood cells lineages; approximately 60% of patients exhibited improvements in all three blood cell lineages: hemoglobin, neutrophil and platelet counts, that are above the initial criteria for inclusion in the study; 13 patients were transfusion dependent at baseline, 6 of those became transfusion independent at six-month follow up.

ShowHide Related Items >><<
PSTI Pluristem
$4.55 /

+0.08 (+1.79%)

PSTI Pluristem
$4.55 /

+0.08 (+1.79%)

12/10/20 H.C. Wainwright
Pluristem price target lowered to $9 from $15.50 at H.C. Wainwright
12/10/20 Jefferies
Pluristem downgraded to Hold from Buy at Jefferies
07/24/20 Jefferies
Pluristem price target raised to $16 from $12 at Jefferies
06/22/20 Dawson James
Channel checks dispute NY Times' COVID contention, says Dawson James
PSTI Pluristem
$4.55 /

+0.08 (+1.79%)

PSTI Pluristem
$4.55 /

+0.08 (+1.79%)

Over a month ago
Options
Largest borrow rate increases among liquid names » 08:45
03/22/21
03/22
08:45
03/22/21
08:45
EARS

Auris Medical

$4.01 /

+0.04 (+1.01%)

, INMD

InMode

$71.17 /

+1.46 (+2.09%)

, NBRV

Nabriva Therapeutics

$2.04 /

+0.055 (+2.78%)

, GPL

Great Panther Mining

$0.85 /

+0.02 (+2.42%)

, ARKF

ARK Fintech Innovation ETF

$53.22 /

+0.95 (+1.82%)

, PSTI

Pluristem

$5.57 /

+0.08 (+1.46%)

, APPH

AppHarvest

$21.48 /

-0.36 (-1.65%)

, NMM

Navios Maritime Partners

$26.90 /

+1.67 (+6.62%)

, CLOV

Clover Health

$8.53 /

+0.085 (+1.01%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: Auris Medical (EARS) 56.73% +0.83, InMode (INMD) 3.91% +0.83, Nabriva Therapeutics (NBRV) 12.86% +0.68, Great Panther Silver (GPL) 13.59% +0.62, Ark Fintech Innovation (ARKF) 3.05% +0.39, Pluristem (PSTI) 32.66% +0.27, AppHarvest (APPH) 24.93% +0.25, CC Neuberger Principal Holdings II (PRPB) 0.48% +0.23, Navios Maritime Partners (NMM) 4.71% +0.20, and Clover Health (CLOV) 2.39% +0.17.

ShowHide Related Items >><<
PSTI Pluristem
$5.57 /

+0.08 (+1.46%)

NMM Navios Maritime Partners
$26.90 /

+1.67 (+6.62%)

NBRV Nabriva Therapeutics
$2.04 /

+0.055 (+2.78%)

INMD InMode
$71.17 /

+1.46 (+2.09%)

GPL Great Panther Mining
$0.85 /

+0.02 (+2.42%)

EARS Auris Medical
$4.01 /

+0.04 (+1.01%)

CLOV Clover Health
$8.53 /

+0.085 (+1.01%)

APPH AppHarvest
$21.48 /

-0.36 (-1.65%)

EARS Auris Medical
$4.01 /

+0.04 (+1.01%)

INMD InMode
$71.17 /

+1.46 (+2.09%)

02/11/21 Baird
InMode price target raised to $84 from $58 at Baird
02/11/21 Canaccord
InMode price target raised to $80 from $69 at Canaccord
02/11/21 UBS
InMode price target raised to $84 from $64 at UBS
10/21/20 Canaccord
InMode price target raised to $51 from $42 at Canaccord
NBRV Nabriva Therapeutics
$2.04 /

+0.055 (+2.78%)

03/12/21 Northland
Nabriva Therapeutics price target lowered to $6 from $9 at Northland
06/22/20 Northland
Nabriva Therapeutics price target lowered to $1.50 from $2.50 at Northland
04/23/20 Northland
Nabriva Therapeutics price target lowered to $2.50 from $5 at Northland
04/09/20 H.C. Wainwright
Nabriva Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
GPL Great Panther Mining
$0.85 /

+0.02 (+2.42%)

10/29/20 Roth Capital
Great Panther Mining resumed with a Buy at Roth Capital
09/09/20 Alliance Global Partners
Great Panther Mining transferred with a Buy at Alliance Global Partners
07/10/20 Alliance Global Partners
Great Panther price target raised to 80c from 65c at Alliance Global
07/10/20 H.C. Wainwright
Great Panther Mining price target raised to $2 from $1.75 at H.C. Wainwright
ARKF ARK Fintech Innovation ETF
$53.22 /

+0.95 (+1.82%)

PSTI Pluristem
$5.57 /

+0.08 (+1.46%)

12/10/20 H.C. Wainwright
Pluristem price target lowered to $9 from $15.50 at H.C. Wainwright
12/10/20 Jefferies
Pluristem downgraded to Hold from Buy at Jefferies
07/24/20 Jefferies
Pluristem price target raised to $16 from $12 at Jefferies
06/22/20 Dawson James
Channel checks dispute NY Times' COVID contention, says Dawson James
APPH AppHarvest
$21.48 /

-0.36 (-1.65%)

02/11/21
Fly Intel: Top five analyst initiations
02/11/21 Cowen
AppHarvest appealing to food and water investors, Cowen starts with Outperform
02/11/21 Cowen
AppHarvest initiated with an Outperform at Cowen
NMM Navios Maritime Partners
$26.90 /

+1.67 (+6.62%)

02/24/21 Citi
Navios Maritime Partners price target raised to $21 from $7.50 at Citi
01/29/21 Janney Montgomery Scott
Navios Maritime Partners price target raised to $20 from $15 at Janney Montgomery Scott
01/08/21 Jefferies
Navios Maritime Partners upgraded to Buy, price target doubled at Jefferies
01/08/21 Jefferies
Navios Maritime Partners upgraded to Buy from Hold at Jefferies
CLOV Clover Health
$8.53 /

+0.085 (+1.01%)

03/09/21 Credit Suisse
Clover Health initiated with a Neutral at Credit Suisse
03/03/21 Citi
Clover Health price target lowered to $13 from $19 at Citi
02/02/21
Fly Intel: Top five analyst initiations
02/02/21 Citi
Clover Health initiated with a Buy at Citi
NBRV Nabriva Therapeutics
$2.04 /

+0.055 (+2.78%)

INMD InMode
$71.17 /

+1.46 (+2.09%)

GPL Great Panther Mining
$0.85 /

+0.02 (+2.42%)

  • 11
    Dec
EARS Auris Medical
$4.01 /

+0.04 (+1.01%)

CLOV Clover Health
$8.53 /

+0.085 (+1.01%)

PSTI Pluristem
$5.57 /

+0.08 (+1.46%)

NBRV Nabriva Therapeutics
$2.04 /

+0.055 (+2.78%)

EARS Auris Medical
$4.01 /

+0.04 (+1.01%)

CLOV Clover Health
$8.53 /

+0.085 (+1.01%)

PSTI Pluristem
$5.57 /

+0.08 (+1.46%)

INMD InMode
$71.17 /

+1.46 (+2.09%)

GPL Great Panther Mining
$0.85 /

+0.02 (+2.42%)

EARS Auris Medical
$4.01 /

+0.04 (+1.01%)

CLOV Clover Health
$8.53 /

+0.085 (+1.01%)

ARKF ARK Fintech Innovation ETF
$53.22 /

+0.95 (+1.82%)

APPH AppHarvest
$21.48 /

-0.36 (-1.65%)

ARKF ARK Fintech Innovation ETF
$53.22 /

+0.95 (+1.82%)

Over a quarter ago
Syndicate
Pluristem raises $30M in a registered direct offering » 09:12
02/02/21
02/02
09:12
02/02/21
09:12
PSTI

Pluristem

$7.47 /

+0.48 (+6.87%)

Pluristem has entered…

Pluristem has entered into definitive agreements with institutional investors for the purchase and sale of 4,761,905 shares of its common stock at a purchase price of $6.30 per share in a registered direct offering. A.G.P./Alliance Global Partners is acting as sole placement agent for the offering.

ShowHide Related Items >><<
PSTI Pluristem
$7.47 /

+0.48 (+6.87%)

PSTI Pluristem
$7.47 /

+0.48 (+6.87%)

12/10/20 H.C. Wainwright
Pluristem price target lowered to $9 from $15.50 at H.C. Wainwright
12/10/20 Jefferies
Pluristem downgraded to Hold from Buy at Jefferies
07/24/20 Jefferies
Pluristem price target raised to $16 from $12 at Jefferies
06/22/20 Dawson James
Channel checks dispute NY Times' COVID contention, says Dawson James
PSTI Pluristem
$7.47 /

+0.48 (+6.87%)

PSTI Pluristem
$7.47 /

+0.48 (+6.87%)

Hot Stocks
Pluristem receives Nasdaq approval for market listing » 07:05
01/27/21
01/27
07:05
01/27/21
07:05
PSTI

Pluristem

$7.33 /

-0.12 (-1.61%)

Pluristem Therapeutics…

Pluristem Therapeutics announced that effective as of market open on January 29 its common shares have been approved for listing to the Nasdaq Global Market and will continue trading under the company's current ticker symbol. A listing on the Nasdaq Global Market is considered an indicator of status and success for companies that qualify for listing. Listed companies must satisfy stringent financial, liquidity and corporate governance requirements, both initially and on an ongoing basis.

ShowHide Related Items >><<
PSTI Pluristem
$7.33 /

-0.12 (-1.61%)

PSTI Pluristem
$7.33 /

-0.12 (-1.61%)

12/10/20 H.C. Wainwright
Pluristem price target lowered to $9 from $15.50 at H.C. Wainwright
12/10/20 Jefferies
Pluristem downgraded to Hold from Buy at Jefferies
07/24/20 Jefferies
Pluristem price target raised to $16 from $12 at Jefferies
06/22/20 Dawson James
Channel checks dispute NY Times' COVID contention, says Dawson James
PSTI Pluristem
$7.33 /

-0.12 (-1.61%)

PSTI Pluristem
$7.33 /

-0.12 (-1.61%)

Options
Largest borrow rate increases among liquid names » 08:45
01/22/21
01/22
08:45
01/22/21
08:45
LMND

Lemonade

$148.19 /

+3.19 (+2.20%)

, OPEN

Opendoor Technologies

$29.70 /

-0.3 (-1.00%)

, AXU

Alexco Resource

$2.72 /

-0.08 (-2.86%)

, PSTI

Pluristem

$7.36 /

-0.56 (-7.07%)

, ERJ

Embraer

$6.63 /

-0.29 (-4.19%)

, GSAT

Globalstar

$1.24 /

-0.165 (-11.79%)

, OBSV

ObsEva

$4.12 /

-0.37 (-8.24%)

, BGS

B&G Foods

$29.57 /

-0.05 (-0.17%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: Lemonade (LMND) 32.70% +15.56, Opendoor Technologies (OPEN) 68.52% +3.84, Alexco Resource (AXU) 28.28% +2.08, Advisorshares Pure Us Cannabis ETF (MSOS) 3.53% +0.60, Pluristem (PSTI) 37.23% +0.42, Embraer (ERJ) 0.81% +0.38, Globalstar (GSAT) 3.28% +0.28, ObsEva (OBSV) 7.43% +0.18, ProShares UltraPro Short Dow 30 (SDOW) 1.03% +0.16, and B&G Foods (BGS) 3.04% +0.16.

ShowHide Related Items >><<
PSTI Pluristem
$7.36 /

-0.56 (-7.07%)

OPEN Opendoor Technologies
$29.70 /

-0.3 (-1.00%)

OBSV ObsEva
$4.12 /

-0.37 (-8.24%)

LMND Lemonade
$148.19 /

+3.19 (+2.20%)

GSAT Globalstar
$1.24 /

-0.165 (-11.79%)

ERJ Embraer
$6.63 /

-0.29 (-4.19%)

BGS B&G Foods
$29.57 /

-0.05 (-0.17%)

AXU Alexco Resource
$2.72 /

-0.08 (-2.86%)

LMND Lemonade
$148.19 /

+3.19 (+2.20%)

01/21/21 Piper Sandler
Lemonade price target raised to $163 from $105 at Piper Sandler
11/23/20 Morgan Stanley
Root initiated with an Equal Weight at Morgan Stanley
11/12/20 Piper Sandler
Lemonade price target raised to $71 from $63 at Piper Sandler
11/02/20 Piper Sandler
Lemonade initiated with an Overweight at Piper Sandler
OPEN Opendoor Technologies
$29.70 /

-0.3 (-1.00%)

01/06/21 Wedbush
Wedbush bullish on Opendoor Technologies, initiates with an Outperform
01/06/21 Wedbush
Opendoor Technologies initiated with an Outperform at Wedbush
12/29/20 BTIG
Opendoor Technologies initiated with a Neutral at BTIG
12/21/20 Oppenheimer
Opco downgrades Redfin on 'overly optimistic' market valuation
AXU Alexco Resource
$2.72 /

-0.08 (-2.86%)

01/15/21 Alliance Global Partners
Alexco Resource initiated with a Buy at Alliance Global Partners
PSTI Pluristem
$7.36 /

-0.56 (-7.07%)

12/10/20 H.C. Wainwright
Pluristem price target lowered to $9 from $15.50 at H.C. Wainwright
12/10/20 Jefferies
Pluristem downgraded to Hold from Buy at Jefferies
07/24/20 Jefferies
Pluristem price target raised to $16 from $12 at Jefferies
06/22/20 Dawson James
Channel checks dispute NY Times' COVID contention, says Dawson James
ERJ Embraer
$6.63 /

-0.29 (-4.19%)

08/11/20
Fly Intel: Top five analyst downgrades
08/11/20 Morgan Stanley
Embraer downgraded to Underweight from Equal Weight at Morgan Stanley
05/04/20 BofA
Embraer downgraded to Neutral from Buy at BofA
04/28/20 Credit Suisse
Embraer downgraded to Underperform from Neutral at Credit Suisse
GSAT Globalstar
$1.24 /

-0.165 (-11.79%)

01/22/21 Morgan Stanley
Globalstar downgraded to Underweight after 266% rally at Morgan Stanley
01/22/21 Morgan Stanley
Globalstar downgraded to Underweight from Equal Weight at Morgan Stanley
OBSV ObsEva
$4.12 /

-0.37 (-8.24%)

01/04/21 H.C. Wainwright
ObsEva price target lowered to $17 from $23 at H.C. Wainwright
11/09/20 JPMorgan
ObsEva downgraded to Underweight from Neutral at JPMorgan
10/05/20 H.C. Wainwright
ObsEva price target lowered to $23 from $36 at H.C. Wainwright
07/07/20 Wedbush
Selloff in ObsEva shares 'overdone,' says Wedbush
BGS B&G Foods
$29.57 /

-0.05 (-0.17%)

01/19/21 Stephens
B&G Foods initiated with an Equal Weight at Stephens
01/05/21 Credit Suisse
B&G Foods downgraded to Underperform from Neutral at Credit Suisse
07/28/20 Seaport Global
B&G Foods initiated with a Neutral at Seaport Global
06/12/20
Fly Intel: Top five analyst initiations
OBSV ObsEva
$4.12 /

-0.37 (-8.24%)

LMND Lemonade
$148.19 /

+3.19 (+2.20%)

ERJ Embraer
$6.63 /

-0.29 (-4.19%)

BGS B&G Foods
$29.57 /

-0.05 (-0.17%)

  • 14
    Jan
  • 30
    Oct
  • 02
    Jul
  • 25
    Mar
LMND Lemonade
$148.19 /

+3.19 (+2.20%)

PSTI Pluristem
$7.36 /

-0.56 (-7.07%)

OPEN Opendoor Technologies
$29.70 /

-0.3 (-1.00%)

OBSV ObsEva
$4.12 /

-0.37 (-8.24%)

LMND Lemonade
$148.19 /

+3.19 (+2.20%)

GSAT Globalstar
$1.24 /

-0.165 (-11.79%)

BGS B&G Foods
$29.57 /

-0.05 (-0.17%)

PSTI Pluristem
$7.36 /

-0.56 (-7.07%)

OPEN Opendoor Technologies
$29.70 /

-0.3 (-1.00%)

LMND Lemonade
$148.19 /

+3.19 (+2.20%)

GSAT Globalstar
$1.24 /

-0.165 (-11.79%)

ERJ Embraer
$6.63 /

-0.29 (-4.19%)

BGS B&G Foods
$29.57 /

-0.05 (-0.17%)

AXU Alexco Resource
$2.72 /

-0.08 (-2.86%)

Hot Stocks
Pluristem appoints Maital Shemesh-Rasmussen, Rami Levi to board » 07:41
01/06/21
01/06
07:41
01/06/21
07:41
PSTI

Pluristem

$7.22 /

+0.11 (+1.55%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

Pluristem Therapeutics…

Pluristem Therapeutics (PTSI) announced the appointment of Ms. Maital Shemesh-Rasmussen and Mr. Rami Levi to its Board of Directors. Shemesh-Rasmussen served as Global Head of Solution Marketing at Roche Diagnostics Information Solutions (RHHBY), where she defined Roche's new health-tech strategy. Levi is the Founder and President of Catalyst Group International.

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

PSTI Pluristem
$7.22 /

+0.11 (+1.55%)

PSTI Pluristem
$7.22 /

+0.11 (+1.55%)

12/10/20 H.C. Wainwright
Pluristem price target lowered to $9 from $15.50 at H.C. Wainwright
12/10/20 Jefferies
Pluristem downgraded to Hold from Buy at Jefferies
07/24/20 Jefferies
Pluristem price target raised to $16 from $12 at Jefferies
06/22/20 Dawson James
Channel checks dispute NY Times' COVID contention, says Dawson James
RHHBY Roche
$0.00 /

+ (+0.00%)

01/04/21 JPMorgan
Roche downgraded to Neutral from Overweight at JPMorgan
12/28/20 Piper Sandler
Ionis partner data inconclusive in Huntington's disease, says Piper Sandler
12/21/20 JPMorgan
Roche should rally 1%-2% on 'positive surprise,' says JPMorgan
12/08/20 Roth Capital
Turning Point Therapeutics price target raised to $140 from $133 at Roth Capital
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PSTI Pluristem
$7.22 /

+0.11 (+1.55%)

PSTI Pluristem
$7.22 /

+0.11 (+1.55%)

Hot Stocks
Pluristem enters collaboration with Innovare R&D to expand PLX cell program » 07:04
12/29/20
12/29
07:04
12/29/20
07:04
PSTI

Pluristem

$7.12 /

-0.085 (-1.18%)

Pluristem Therapeutics…

Pluristem Therapeutics announced it has entered into a collaboration agreement with Mexican pharmaceutical company Innovare R&D to expand its ongoing clinical program of PLX cells in the treatment of Acute Respiratory Distress Syndrome associated with COVID-19 in Mexico. The Phase II study in Mexico is subject to the approval of local authorities, with the goal of being conducted under the U.S. Food and Drug Administration cleared protocol. In accordance with the agreement, Innovare will open clinical sites and enroll patients for the proposed clinical study in Mexico. Innovare will fund the study in Mexico and will purchase PLX cells for the study from Pluristem. Subject to potential positive clinical study results and Mexican regulatory approval for commercialization, the agreement grants Innovare exclusive distribution rights in Mexico to supply PLX cells for treating severe COVID-19 cases complicated by ARDS. All intellectual property and manufacturing rights remain with Pluristem. With 1,389,430 cases and 122,855 deaths as of December 29, 2020, Mexico's COVID-19 infection and mortality rates have been increasing. Mexico has the highest deaths proportionally to COVID-19 cases or population in the world as of December 28, 2020, as reported by Johns Hopkins University of Medicine. Pluristem is currently conducting two Phase II studies in ARDS associated with COVID-19 in the U.S., Europe and Israel, an Expanded Access Program in the U.S. and a per patient compassionate use program in Israel.

ShowHide Related Items >><<
PSTI Pluristem
$7.12 /

-0.085 (-1.18%)

PSTI Pluristem
$7.12 /

-0.085 (-1.18%)

12/10/20 H.C. Wainwright
Pluristem price target lowered to $9 from $15.50 at H.C. Wainwright
12/10/20 Jefferies
Pluristem downgraded to Hold from Buy at Jefferies
07/24/20 Jefferies
Pluristem price target raised to $16 from $12 at Jefferies
06/22/20 Dawson James
Channel checks dispute NY Times' COVID contention, says Dawson James
PSTI Pluristem
$7.12 /

-0.085 (-1.18%)

PSTI Pluristem
$7.12 /

-0.085 (-1.18%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.